Soleno Therapeutics price target raised to $97 from $81 at Guggenheim

Guggenheim raised the firm’s price target on Soleno Therapeutics (SLNO) to $97 from $81 and keeps a Buy rating on the shares. Skyclarys comparisons imply Vykat’s uptake is tracking inline with Skyclarys and given these trends and MMA progress, the firm is increasing its target following Soleno’s Q1 report citing the “good early demand.”